Last reviewed · How we verify

NCT05004246

Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study

Status unknown Last updated 18 March 2024
What this trial tests

trial in Prognosis in 1,000 participants. Status unknown.

Timeline
15 March 2021
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorTongji Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date15 March 2021
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across China

Conditions studied

Sponsor

Tongji Hospital

Who can join

Eligibility, any sex, with Prognosis or Sequelae. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Follow-up study of Coronavirus disease 2019 (COVID-19) survivors has rarely been reported. We aimed to investigate longitudinal changes in the characteristics of COVID-19 survivors after discharge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prognosis

Currently open trials in the same condition.

Other Tongji Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05004246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing